Open AccessTargeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator
Author(s) -
Adrian Vella,
Jennifer L. R. Freeman,
Imogene Dunn,
Kit A. Keller,
John B. Buse,
Carmen Valcarce
Publication year - 2019
Publication title -
science translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.819
H-Index - 216
eISSN - 1946-6242
pISSN - 1946-6234
DOI - 10.1126/scitranslmed.aau3441
Subject(s) - glucokinase , diabetes mellitus , activator (genetics) , medicine , endocrinology , biology , receptor
A hepatoselective glucokinase activator reduced hyperglycemia without hypoglycemia or adverse effects on lipids, liver enzymes, or blood pressure.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom